FDA Approves KV’s Drug Manufacturing Plan

Law360, New York (September 2, 2009, 6:40 PM EDT) -- The U.S. Food and Drug Administration has signed off on KV Pharmaceutical Co.’s work plan that aims to clear up problems with its drug manufacturing and distribution practices, according to a filing with the U.S. Securities and Exchange Commission.

KV said Wednesday the FDA has accepted its work plan several months after the St. Louis-based company agreed to a consent decree with the agency that enjoined KV, its subsidiaries Ethex Corp. and Ther-Rx Corp., and its principal officers from making and distributing adulterated and unapproved drugs....
To view the full article, register now.